The patient has elective or planned major surgery to be performed during the course of the clinical trial Major surgery within 4 weeks Have a planned major surgery. Elective or planned major surgery to be performed during the course of the trial Major surgery within 3 weeks of scheduled C1D1 dosing. Recent major surgery within 4 weeks prior to first infusion Patients who are less than 4 weeks post-op after major surgery Major surgery within 2 weeks prior to trial entry; Patients with elective or planned major surgery to be performed during the course of the clinical trial Has had major surgery in the past 4 weeks. Major surgery Major surgery in the last three weeks At least 2 weeks must have elapsed since undergoing major surgery Patients who may require major surgery during the course of the study At least 3 weeks from major surgery Major surgery or radiation within 4 weeks prior to study entry Major surgery: 6 weeks The patient has elective or planned major surgery to be performed during the course of the clinical trial All major surgery including prior surgery to the brain within 3 weeks of commencement of study therapy At least 4 weeks since major surgery or radiation therapy Any major surgery, as determined by the Investigator, within 4 weeks of IMP administration Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study Major surgery: ?2 weeks Major surgery ? 2 weeks prior to starting CC-90002. Patients who have had major surgery within 6 weeks prior to the first dose of study drug or have major surgery planned during the first 12 weeks after MT-3724 has finished. Major surgery (as defined by the Investigator): ?4 weeks No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment Known bleeding risk including serious hemorrhage or hemoptysis within the last 3 months; major surgery within the past 8 weeks or minor surgery within the past 4 weeks The participant has electively planned or will require major surgery during the course of the study. Major surgery within 4 weeks before screening Major surgery within the past 2 months Have electively planned or will require major surgery during the course of the study. < 2 weeks since major surgery (i.e., laparotomy or thoracotomy) Major surgery performed within 4 weeks of study entry Major surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgery Had major surgery ? 4 weeks of C1D1 Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to first trial treatment or planned within 12 months after screening, e.g.,hip replacement Received major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administration Major surgery within prior 4 weeks and minor surgery within 7 days; Major surgery in the last two weeks of starting study therapy; this does not include procedures like biopsy (needle or excisional) or port placement as these are not considered as major surgery Major surgery without full recovery or major surgery within 3 weeks of screening The patient has elective or planned major surgery to be performed during the course of the clinical trial Major surgery within 3 weeks prior to event 1 CAPMATINIB EXCLUSION CRITERIA: Major surgery (e.g., intrathoracic, intraabdominal or intrapelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure At least 4 weeks from major surgery Major surgery within 12 weeks of enrolment Major surgery within 4 weeks of starting study treatment The patient has elective or planned major surgery to be performed during the course of the clinical trial Major surgery within 4 weeks of initiation of therapy; clearance letter from primary physician required Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study Major surgery in the past 4 weeks. A history of any major surgery within 6 weeks prior to dosing Any major surgery within the last 3 weeks Patients who have had major surgery within 4 weeks of initiation of study medication Major surgery in the past 16 weeks Major surgery within two weeks prior to trial entry > 4 weeks since major surgery >= 2 weeks since major surgery Major surgery, other than diagnostic surgery, within 2 weeks Planned major surgery Major surgery within 4 weeks prior to study treatment. Major surgery in last 4 weeks, minor surgery in the last 2 weeks Major surgery within 4 weeks prior to starting INC280 Major surgery/surgical therapy for any cause within 4 weeks of Screening; Elective or planned major surgery to be performed during the course of the trial Major surgery within 4 weeks prior to study entry Any major surgery within the last four weeks. Has received major surgery within the 4 weeks prior to starting the trial. Any major surgery within the last four weeks. Major surgery within the last 4 weeks; minor surgery within the last 2 weeks Major surgery within 4 weeks prior to inclusion At least 4 weeks must have elapsed since the last chemotherapy, radiotherapy or major surgery Major surgery within four weeks before first IMP administration. Planned major surgery during the study Patients who are less than 4 weeks post-operative (op) after major surgery No planned major surgery Planned major surgery Major surgery without full recovery or major surgery within 3 weeks of Screening. Minimum of four weeks since any major surgery, completion of radiation Patients less than 4 weeks post major surgery Major surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgery Major surgery within 4 weeks prior to the screening visit Major surgery within 4 weeks prior to screening. Participants with major surgery in the 4 weeks prior to randomization (Video-assisted thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery). Major surgery for any reason, except diagnostic biopsy, within 4 weeks of enrolment and/or if the subject has not fully recovered from the surgery within 4 weeks of enrolment Subject has had major surgery, other than diagnostic surgery, within 4 weeks prior to treatment in study. Major surgery 4 weeks from any major surgery Major surgery within 4 weeks of random assignment Major surgery within 4 weeks prior to entering the study Recovery from any major or minor surgeries; patient must be 4 weeks post-major surgery and 2 weeks post-minor surgery Major surgery within the last 4 weeks; minor surgery within the last 2 weeks Major surgery within 4 weeks prior to entering the study Any major surgery or radiation therapy within four weeks. Patients that may require major surgery during the course of the study Major surgery within 4 weeks >= 2 weeks since major surgery Major surgery, other than diagnostic surgery, within 2 weeks Patient has had major surgery within the last 3 weeks Major surgery within 4 weeks of study randomisation. At least 4 weeks must have elapsed from major surgery Any major surgery within 4 weeks of starting treatment on protocol Recent major surgery (within 4 weeks), other than for diagnosis Major surgery within 4 weeks (or within 2 weeks following consultation with and approval of Medical Monitor) Major surgery within 4 weeks of screening Major surgery or irradiation within two weeks Major surgery or irradiation within two weeks Elective or a planned major surgery while on study treatment Major surgery within 4 weeks prior to entry The participant has a history of major surgery or treatment other cancer therapy within 2-6 weeks before starting the study Major surgery within 2 weeks Major surgery within 4 weeks (less than 28 days) prior to C1D1 Major surgery within 4 weeks prior to C1D1 Major surgery within 4 weeks of C1D1 Major surgery within 4 weeks Major trauma or surgery w/in prior 4 weeks Major surgery within the last 2 weeks Major surgery other than diagnostic surgery =< 4 weeks At least 3 weeks from major surgery with full recovery No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment Major surgery (as judged by the investigator) within 4 weeks Major surgery or trauma within 4 weeks Major surgery within 4 weeks prior to IP administration Subjects may not have any major surgery within 4 weeks At least 4 weeks from prior major surgery or radiotherapy Patients who have had major surgery within 4 weeks of initiation of study medication Has an elective or planned major surgery to be performed during the course of the trial Elective or a planned major surgery At least 4 weeks from prior major surgery or radiotherapy. Radiotherapy or major surgery within 4 weeks Major surgery within preceding 8 weeks Major surgery within the past 2 weeks. Patient is planning major surgery within the next 6 months Major surgery within 4 weeks or till recovery to baseline functioning (per patient) whichever is shorter Major surgery within four weeks before consent date Major surgery within the past 2 weeks Undergoing major surgery Patients who have had major surgery within 4 weeks of initiation of study medication Any major surgery within the last four weeks. Major surgery within 2 weeks Major surgery within 4 weeks prior to C1D1. A minimum of 4 weeks from any major surgery prior to enrollment; coincident standard of care surgery with the research biopsy is permitted during the study Major surgery within 4 weeks Major surgery in the past 8 weeks (Arms 1 and 4) Any chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14 days. Major surgery (eg, laparotomy, thoracotomy or joint replacement) within 3 weeks prior to randomization or elective surgery scheduled to be performed during the study.